
1. nat commun. 2017 may 24;8:15159. doi: 10.1038/ncomms15159.

a tetraoxane-based antimalarial drug candidate overcomes pfk13-c580y
dependent artemisinin resistance.

o'neill pm(1)(2), amewu rk(1), charman sa(3), sabbani s(1), gnädig nf(4),
straimer j(4), fidock da(4)(5), shore er(1), roberts nl(1), wong mh(1), hong
wd(1), pidathala c(1), riley c(1), murphy b(1), aljayyoussi g(6), gamo fj(7),
sanz l(7), rodrigues j(7), cortes cg(7), herreros e(7), angulo-barturén i(7),
jiménez-díaz mb(7), bazaga sf(7), martínez-martínez ms(7), campo b(8), sharma
r(6), ryan e(3), shackleford dm(3), campbell s(8), smith da(8), wirjanata g(9),
noviyanti r(10), price rn(9)(11), marfurt j(9), palmer mj(8), copple im(2),
mercer ae(2), ruecker a(12), delves mj(12), sinden re(12)(13), siegl p(8), davies
j(6), rochford r(14), kocken chm(15), zeeman am(15), nixon gl(1), biagini ga(6), 
ward sa(6).

author information: 
(1)department chemistry, university liverpool, liverpool l69 7zd, uk.
(2)department pharmacology, school biomedical sciences, mrc centre drug
safety science, university liverpool, liverpool l69 3ge uk.
(3)centre drug candidate optimisation, monash institute pharmaceutical
sciences, monash university, 381 royal parade, parkville, victoria 3052,
australia.
(4)department microbiology immunology, columbia university college of
physicians surgeons, hhsc 1502, 701 w. 169th street, new york, new york
10032, usa.
(5)division infectious diseases, department medicine, columbia university
medical center, hhsc 1502, 701 w. 168th street, new york, new york 10032, usa.
(6)research centre drugs diagnostics, liverpool school tropical
medicine, pembroke place, liverpool l3 5qa, uk.
(7)tres cantos medicines development campus, ddw, glaxosmithkline, severo ochoa
2, 28760 tres cantos, spain.
(8)medicines malaria venture, icc, route de pré-bois 20, p.o. box 1826, 1215 
geneva, switzerland.
(9)global tropical health division, menzies school health research,
charles darwin university, p.o. box 41096, casuarina, darwin, northern territory 
0811, australia.
(10)eijkman institute molecular biology, jl. diponegoro 69, 10430 jakarta,
indonesia.
(11)nuffield department clinical medicine, centre tropical medicine and
global health, university oxford, old road campus, roosevelt drive, oxford ox3
7fz, uk.
(12)department life sciences, imperial college london, south kensington,
london sw7 2az, uk.
(13)nuffield department medicine, jenner institute, university oxford, 
old road campus research building, roosevelt drive, oxford, ox3 7dq, uk.
(14)department immunology microbiology, university colorado, aurora
colorado, co 80045, usa.
(15)department parasitology, biomedical primate research centre, p. o. box
3306, 2280 gh rijswijk, netherlands.

k13 gene mutations primary marker artemisinin resistance plasmodium
falciparum malaria threatens long-term clinical utility of
artemisinin-based combination therapies, cornerstone modern day malaria
treatment. describe multinational drug discovery programme has
delivered synthetic tetraoxane-based molecule, e209, meets key
requirements medicines malaria venture drug candidate profiles. e209
has potent nanomolar inhibitory activity multiple strains p.
falciparum p. vivax vitro, efficacious p. falciparum vivo
rodent models, produces parasite reduction ratios equivalent to
dihydroartemisinin pharmacokinetic pharmacodynamic characteristics
compatible single-dose cure. vitro studies transgenic parasites
expressing variant forms k13 show cross-resistance c580y mutation,
the primary variant observed southeast asia. e209 superior next
generation endoperoxide combined pharmacokinetic pharmacodynamic
features overcome liabilities artemisinin derivatives.

doi: 10.1038/ncomms15159 
pmcid: pmc5458052
pmid: 28537265  [indexed medline]

